Toripalimab Plus Axitinib May Be New Standard First-Line Treatment for Advanced RCC

Toripalimab plus axitinib can improve PFS, when compared to sunitinib, in treatment-naïve, advanced RCC, a phase 3 trial suggests.

Related Keywords

Peking ,Beijing ,China ,Madrid ,Spain ,Xinan Sheng ,University Cancer Hospital ,Shanghai Junshi Biosciences Co ,Peking University Cancer Hospital ,Shanghai Junshi Biosciences ,